FRIZZLED7 Is Required for Tumor Initiation and Metastatic Growth of Melanoma Cells

PLoS One. 2016 Jan 25;11(1):e0147638. doi: 10.1371/journal.pone.0147638. eCollection 2016.

Abstract

Metastases are thought to arise from cancer stem cells and their tumor initiating abilities are required for the establishment of metastases. Nevertheless, in metastatic melanoma, the nature of cancer stem cells is under debate and their contribution to metastasis formation remains unknown. Using an experimental metastasis model, we discovered that high levels of the WNT receptor, FZD7, correlated with enhanced metastatic potentials of melanoma cell lines. Knocking down of FZD7 in a panel of four melanoma cell lines led to a significant reduction in lung metastases in animal models, arguing that FZD7 plays a causal role during metastasis formation. Notably, limiting dilution analyses revealed that FZD7 is essential for the tumor initiation of melanoma cells and FZD7 knockdown impeded the early expansion of metastatic melanoma cells shortly after seeding, in accordance with the view that tumor initiating ability of cancer cells is required for metastasis formation. FZD7 activated JNK in melanoma cell lines in vitro and the expression of a dominant negative JNK suppressed metastasis formation in vivo, suggesting that FZD7 may promote metastatic growth of melanoma cells via activation of JNK. Taken together, our findings uncovered a signaling pathway that regulates the tumor initiation of melanoma cells and contributes to metastasis formation in melanoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Proliferation
  • Frizzled Receptors / genetics
  • Frizzled Receptors / physiology*
  • Gene Knockdown Techniques
  • Humans
  • Melanoma / genetics
  • Melanoma / pathology*
  • Mutation
  • Neoplasm Metastasis / genetics*
  • Proto-Oncogene Proteins B-raf / genetics
  • Signal Transduction

Substances

  • FZD7 protein, human
  • Frizzled Receptors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf

Grants and funding

This work was funded by the James Wilmot Cancer Center Pilot Grant, University of Rochester Medical Center, (to LX; https://www.urmc.rochester.edu/cancer-institute/researchers/funding-opportunities.aspx), and the IDEA Award for Stem Cell Research from the New York State Department of Health(#N08G-480, to LX; http://stemcell.ny.gov/grants-and-contracts-awarded). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.